Filing Analysis
The Company entered into two separate bridge note agreements totaling $400,000 with its Chairman and CEO, Junli He. These loans are designed to provide immediate liquidity but include conversion rights for the Lender in future equity offerings.
🚩 Red Flags
- Related-party transactions: The CEO is acting as the primary lender to the company.
- Liquidity concerns: Multiple bridge notes from an insider suggest the company may be struggling to secure traditional third-party financing.
- Potential dilution: The Lender has the option to convert debt into equity at the price of future financing, which could dilute existing shareholders.
📋 Key Facts
- May 8, 2026: Entered into a $200,000 Bridge Note with CEO Junli He at 8% annual interest.
- July 16, 2026: Entered into a second $200,000 Bridge Note with CEO Junli He at 8% annual interest.
- Total outstanding principal from these notes is $400,000 as of August 3, 2026.
- Maturity date for both notes is either upon a capital raise of $\ge$ $5,000,000 or one year from the note's execution date.
- Lender has the option to convert the debt into equity if the company raises $\ge$ $200,000 in a subsequent financing.
The Company filed an amendment to its 8-K to correctly report a $300,000 bridge note entered into with its Chairman and CEO, Junli He. This transaction represents a direct financial obligation to an insider that is convertible at the lender's discretion.
🚩 Red Flags
- Related-party transaction: The CEO is acting as the lender to the company.
- Convertible debt held by an insider: Provides the CEO with discretionary conversion rights, which can lead to significant dilution for other shareholders.
- Potential liquidity pressure: The note must be repaid or converted upon a $5M capital raise or within one year.
📋 Key Facts
- The Company entered into a Bridge Note on April 13, 2026, for $300,000.
- The Lender is Junli He, the Chairman and CEO of the Company.
- The note carries an annual fixed interest rate of 8%.
- Repayment is due upon the earlier of April 13, 2027, or a capital raise exceeding $5,000,000 in gross proceeds.
- The Lender (CEO) has the option to convert the note into equity at their discretion.
Harvard Apparatus Regenerative Technology, Inc. reported the results of its Annual Meeting of Stockholders held on June 18, 2026. The meeting included the election of three Class I Directors and the ratification of the company's independent auditor.
📋 Key Facts
- Annual Meeting held on June 18, 2026.
- Junli (Jerry) He, James Shmerling, and Mao Zhang were elected as Class I Directors for one-year terms.
- Stockholders ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for fiscal year ending December 31, 2026.
- A non-binding advisory vote (Say-on-Pay) approved the compensation of named executive officers with 12,467,264 votes in favor.
Harvard Apparatus Regenerative Technology, Inc. entered into Securities Purchase Agreements to conduct a private placement of 1,250,000 shares of common stock for approximately $2.0 million.
🚩 Red Flags
- Dilutive event: Issuance of 1,250,000 new shares will dilute existing shareholders.
- Potential liquidity need: The relatively small size of the offering ($2M) may suggest a need for immediate working capital.
📋 Key Facts
- Date of agreement: July 11, 2025
- Total aggregate purchase price: Approximately $2.0 million
- Number of shares to be issued: 1,250,000 shares of common stock
- Price per share: $1.60
- Transaction type: Private placement via Securities Purchase Agreements under Section 4(a)(2) and Rule 506.
Harvard Apparatus Regenerative Technology, Inc. held its 2025 Annual Meeting of Stockholders on June 20, 2025, where shareholders approved several significant structural changes, most notably an amendment to the Charter to allow for a reverse stock split.
🚩 Red Flags
- Approval of a reverse stock split is often used to maintain exchange listing requirements or combat low share prices (potential signal of distress).
- The combination of a reverse split approval and structural governance changes (declassification/meeting amendments) can indicate significant corporate restructuring.
📋 Key Facts
- Annual Meeting held on June 20, 2025.
- Shareholders approved an amendment to the Charter to effect a reverse split of outstanding common stock; ratio and timing to be determined by the Board.
- Shareholders approved the declassification of directors (Declassification Amendment).
- Shareholders approved an amendment allowing special meetings to be called by holders of at least 35% of voting power.
- Ratification of CBIZ CPAs P.C. as independent auditors for fiscal year ending Dec 31, 2025 was approved.
- Jason Chen and Herman Sanchez were elected as Class III Directors.
Harvard Apparatus Regenerative Technology, Inc. announced the resignation of Marcum LLP as its independent registered public accounting firm and the subsequent engagement of CBIZ CPAs P.C. The filing notes that previous audits included a paragraph expressing substantial doubt about the company's ability to continue as a going concern.
🚩 Red Flags
- Auditor change combined with existing 'going concern' language in previous audit reports.
- Presence of substantial doubt about the company's ability to continue as a going concern for fiscal years 2023 and 2024.
📋 Key Facts
- Marcum LLP resigned as the independent registered public accounting firm on April 11, 2025.
- CBIZ CPAs P.C. was engaged as the new independent registered public accounting firm effective April 11, 2025.
- Audits for fiscal years ended December 31, 2024, and December 31, 2023, included a paragraph expressing substantial doubt about the company's ability to continue as a going concern.
- The registrant stated there were no disagreements with Marcum regarding accounting principles or auditing procedures.
Harvard Apparatus Regenerative Technology, Inc. entered into an exclusive global distribution agreement with Health Regen, Inc. for its consumer health and dietary supplement products. The agreement is set to run from November 1, 2024, through December 31, 2030.
🚩 Red Flags
- High termination penalty: The requirement to pay 3x projected Year 6 sales if the company terminates the deal creates significant contingent liability and limits strategic flexibility.
- Exclusivity risk: Global exclusivity prevents the company from seeking other distribution partners for these products until 2031.
📋 Key Facts
- Agreement signed on October 31, 2024, with Health Regen, Inc. (the 'Distributor').
- Exclusivity period: November 1, 2024, to December 31, 2030.
- The Company is granted global exclusivity; it cannot authorize other third parties to sell the Products during this term.
- Revenue model includes a mark-up fee on manufacturing costs and pass-through for procured services.
- Termination penalty: If the Company terminates early, it must pay the Distributor three times the projected annual sales in year 6 of the agreement.
Harvard Apparatus Regenerative Technology, Inc. announced the appointment of Mao Zhang to its Board of Directors as a Class I director, effective August 26, 2024.
📋 Key Facts
- Mao Zhang (Founder and CEO of Stellars Capital) appointed as Class I Director on August 26, 2024.
- Term runs until the 2026 annual meeting or until successor is elected/qualified.
- Compensation includes $25,000 in stock options vesting over one year (quarterly increments).
- Annual cash compensation of $20,000 paid in quarterly increments.
- Standard reimbursement for board and committee meeting expenses.
Harvard Apparatus Regenerative Technology, Inc. entered into a $5.0 million private placement agreement with an investor for the purchase of 1,388,888 shares at $3.60 per share. The deal includes significant governance concessions, including a Board seat for the investor and proposed charter amendments to allow special meetings and eliminate director classification.
🚩 Red Flags
- Significant governance concessions: The investor is gaining a Board seat and influence over corporate structure.
- Potential for activist-style control: Provisions allowing special meetings and declassifying the board are typical outcomes of distressed financing or aggressive investor intervention.
- Dilutive event: Issuance of 1.38M shares in a private placement.
📋 Key Facts
- Private placement of 1,388,888 shares of common stock.
- Aggregate purchase price: approximately $5.0 million.
- Purchase price per share: $3.60.
- Investor to appoint one member to the Board of Directors.
- Company to seek stockholder approval to eliminate director classification (declassifying the board).
- Company to seek stockholder approval to allow special meetings called by holders of at least 35% of voting power.
Harvard Apparatus Regenerative Technology, Inc. reported the results of its Annual Meeting of Stockholders held on June 20, 2024. The meeting included the election of three Class II Directors and the ratification of Marcum LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 20, 2024.
- David Green, Ting Li, and Ronald Packard were elected to the Board of Directors for three-year terms ending in 2027.
- Stockholders ratified the appointment of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- A non-binding advisory vote (Say-on-Pay) approved the compensation of named executive officers with 8,033,183 votes in favor.
Harvard Apparatus Regenerative Technology, Inc. entered into a private placement agreement to raise $1.5 million through the sale of 367,767 shares of common stock at a price of $4.03 per unit.
🚩 Red Flags
- Dilutive event: Issuance of new equity shares to private investors.
📋 Key Facts
- Date of Agreement: April 15, 2024
- Total aggregate purchase price: $1.5 million
- Number of shares to be issued: 367,767 shares of common stock
- Price per unit: $4.03
- Transaction type: Private placement under Section 4(a)(2) and Rule 506 exemptions
The Company entered into a $500,000 Bridge Note agreement with its Chairman and CEO, Junli He, on February 1, 2024. The loan carries an 8% annual interest rate and is repayable upon the next capital raise of at least $5 million or by February 1, 2025.
🚩 Red Flags
- Related-party transaction involving the CEO/Chairman
- Bridge financing indicates immediate liquidity needs
- The loan includes an optional conversion feature at the discretion of the insider, which can lead to significant dilution for existing shareholders
- Repayment is tied to a specific capital raise threshold ($5M), suggesting potential cash flow constraints
📋 Key Facts
- Lender: Junli He (Chairman and CEO)
- Principal Amount: $500,000
- Interest Rate: 8% annual fixed rate
- Maturity Date: February 1, 2025, or upon a capital raise of at least $5,000,000 (whichever is earlier)
- Conversion Feature: Optional conversion at the discretion of the Lender (CEO)